Financial Performance - The company's main business revenue for the first three quarters of 2023 reached 427 million CNY, representing a year-over-year increase of 23.50% [2] - Net profit attributable to shareholders was 197 million CNY, up 37.91% year-over-year [2] - The company's net profit after deducting non-recurring gains and losses was 192 million CNY, reflecting a 36.52% increase [2] - Earnings per share stood at 2.45 CNY, marking a 19.38% rise [2] Sales Breakdown - Domestic sales revenue amounted to 203 million CNY, with a year-over-year growth of 14.44% [3] - Overseas sales revenue reached 222 million CNY, showing a significant increase of 33.20% [3] - The overall product gross margin was 72.23%, an increase of 2.71 percentage points compared to the same period last year [3] Research and Development - The proportion of R&D personnel in the company reached 22.18%, an increase of 6 percentage points year-over-year [3] - The percentage of R&D staff with master's degrees or higher was 34.55%, up 18.38 percentage points from the previous year [3] - The company has obtained 10 new registration certificates for its products this year [5] Market Expansion - The North American market grew by 48.28%, the Asia-Pacific market by 81.93%, and the South American market by 42.69% from January to September 2024 [4] - The company is establishing a factory in Thailand, expected to commence production and sales by Q2 2025, and is also looking for suitable targets in the US and Europe for potential acquisitions or restructuring [3] Industry Outlook - Despite current challenges in the Chinese economy and healthcare sector, the future remains optimistic due to aging population and increasing medical demands [6] - The market is expected to normalize as policy directions become clearer [6]

Summary of Conference Call Company Overview - The conference call involved Angis, which reported stable growth in its Q3 2024 performance despite macroeconomic challenges and industry disruptions. The company achieved over 50% growth in its credit flow, indicating strong development quality [1][2]. Financial Performance - For Q3 2024, Angis reported total sales revenue of 163 million yuan, a 16.3% increase year-over-year. Cumulative sales revenue reached 427 million yuan, reflecting a 23.5% year-over-year growth. The company achieved a completion rate of 63.3% of its annual budget target, consistent with the previous year [1][2]. - Domestic sales amounted to 203 million yuan, up 14.4% year-over-year, while overseas sales reached 222 million yuan, marking a 33.2% increase, indicating stronger overseas performance [2]. Profitability and Margins - The company’s net profit and gross margin showed positive trends, with gross margins continuing to rise due to effective cost management and operational efficiencies. Sales and management expense ratios decreased, attributed to internal adjustments rather than external factors [6][7]. Industry Dynamics - The call discussed the impact of centralized procurement policies, particularly in the domestic market. The implementation of these policies has been uneven, with ten provinces fully executing procurement processes, while others, like Anhui, have faced delays [4][5]. - The company anticipates that centralized procurement is a transitional policy, with a shift towards a nationwide price linkage system expected to be fully implemented by January 1, 2025. This could diminish the significance of centralized procurement [5][14]. Market Challenges - The domestic market faces significant challenges, including reduced hospital budgets and a decline in procurement activities, with only about 20% of expected tenders being executed. This has led to a decrease in sales of certain medical devices, particularly in the dual-polarity segment [9][12][36]. - The ongoing anti-corruption measures have created uncertainty in the market, affecting hospitals' willingness to engage in procurement and impacting overall sales volumes [11][12]. Future Outlook - Angis is optimistic about its overseas expansion, with significant growth reported in North America (54%), Asia-Pacific (80%), and South America (42%) for Q3. The company has established partnerships for clinical evaluations in Europe and plans to expand its product offerings in these regions [20][21]. - The company is committed to increasing its R&D investments, with plans to launch 10-15 new products in the next two years, despite current market challenges [24][25]. Strategic Initiatives - Angis is focusing on enhancing its product offerings and service capabilities domestically while maintaining a balanced approach to international markets. The company aims to deepen its market penetration and improve service quality to drive growth [30][31]. - The management emphasized the importance of adapting to market conditions and maintaining flexibility in pricing strategies to remain competitive in both domestic and international markets [37][38]. Key Takeaways - Angis has demonstrated resilience in its financial performance amidst challenging market conditions, with a strong focus on overseas growth and product innovation. - The company is navigating complex regulatory environments and market dynamics, with a strategic emphasis on R&D and service enhancement to sustain long-term growth.

Investment Rating - The report maintains a "Recommended" rating for the company [2][5] Core Views - The company has demonstrated steady revenue growth, with a 23.5% year-on-year increase in revenue for the first three quarters, reaching 427 million yuan, and a 37.9% increase in net profit attributable to shareholders, totaling 197 million yuan [3][4] - The company is focusing on product innovation and research and development, particularly in endoscopic diagnosis and treatment, fiber imaging technology, and auxiliary robotics, which are expected to drive long-term growth [4][5] - The company has successfully launched new products, including a replaceable hemostatic clip and an innovative coated guidewire, which have been well-received in the market [4][5] Financial Summary - For the first three quarters of 2024, the company achieved a gross margin of 73.07%, with a slight increase from the previous quarter, indicating strong operational efficiency [4] - The company’s sales expense ratio was 8.57%, down by 1.49%, while the management expense ratio was 7.78%, up by 0.23%, and the R&D expense ratio was 9.55%, up by 2.26%, reflecting a balanced approach to cost management and investment in growth [4] - The projected financial performance for 2024-2026 includes revenue growth from 657 million yuan in 2024 to 1,131 million yuan in 2026, with net profit expected to increase from 268 million yuan to 438 million yuan during the same period [4][6][8]

Financial Performance - Revenue for the third quarter reached RMB 163.26 million, a year-on-year increase of 16.34%[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 73.00 million, up 13.40% year-on-year[2] - Cumulative revenue from the beginning of the year to the end of the reporting period was RMB 427.26 million, a year-on-year increase of 23.53%[2] - Cumulative net profit attributable to shareholders from the beginning of the year to the end of the reporting period was RMB 197.45 million, up 37.91% year-on-year[2] - Operating income for the first three quarters of 2024 reached 427,255,735.56 yuan, a significant increase from 345,881,895.73 yuan in the same period last year[17] - Net profit for the first three quarters of 2024 was 197,452,784.89 yuan, compared to 143,174,996.17 yuan in the same period last year[19] - Operating profit for the first three quarters of 2024 was 230,234,063.11 yuan, compared to 163,799,376.83 yuan in the same period last year[19] - Net profit attributable to parent company shareholders reached RMB 197,452,784.89, an increase from RMB 143,174,996.17 in the previous year[20] - Basic earnings per share (EPS) increased to RMB 2.4499 from RMB 2.0522 year-over-year[20] R&D Investment - R&D investment for the third quarter was RMB 15.58 million, a year-on-year increase of 52.36%, accounting for 9.55% of revenue[3] - Cumulative R&D investment from the beginning of the year to the end of the reporting period was RMB 41.44 million, up 46.77% year-on-year[3] - R&D expenses increased to 41,435,654.28 yuan, up from 28,231,012.70 yuan in the previous year[19] Cash Flow and Financial Position - Net cash flow from operating activities from the beginning of the year to the end of the reporting period was RMB 216.59 million, a year-on-year increase of 50.64%[2] - Cash flow from operating activities was RMB 216,593,741.59, up from RMB 143,785,401.26 in the same period last year[21] - Cash received from sales of goods and services amounted to RMB 473,853,531.45, compared to RMB 343,288,191.11 in the previous year[21] - Cash outflow from investment activities was RMB 3,639,173,424.43, significantly higher than RMB 40,349,666.82 in the prior year[22] - Cash inflow from financing activities reached RMB 1,820,326,000.00, primarily due to subsidiary minority shareholder investments[22] - Net cash flow from financing activities was RMB -114,361,075.58, compared to RMB 1,598,918,645.11 in the previous year[22] - The company's cash and cash equivalents at the end of the period stood at RMB 805,482,331.70, down from RMB 1,971,570,882.45[22] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2.41 billion, a year-on-year increase of 3.29%[3] - Shareholders' equity attributable to the listed company at the end of the reporting period was RMB 2.30 billion, a year-on-year increase of 3.95%[3] - Total assets increased to 2,407,873,095.43 yuan, up from 2,331,074,065.19 yuan in the previous period[16] - Total liabilities decreased to 112,362,683.46 yuan, down from 122,834,954.30 yuan in the previous period[17] - Shareholders' equity increased to 2,295,510,411.97 yuan, up from 2,208,239,110.89 yuan in the previous period[17] - Total non-current assets increased to 193,897,039.30 yuan, up from 184,935,085.18 yuan in the previous period[16] Shareholder Equity and Share Repurchase - The company repurchased 401,398 shares through centralized bidding, accounting for 0.50% of the total shares, with a total payment of 30.9679 million yuan[13] - Basic earnings per share for the third quarter were RMB 0.9028, a year-on-year increase of 13.92%[3] Changes in Financial Assets and Liabilities - The company's monetary funds decreased from 1,954,739,150.26 yuan at the end of 2023 to 805,489,331.70 yuan as of September 30, 2024[15] - The company's trading financial assets increased significantly from 82,419,132.42 yuan at the end of 2023 to 1,280,798,993.53 yuan as of September 30, 2024[15] - The company's accounts receivable decreased from 58,505,242.13 yuan at the end of 2023 to 47,756,747.38 yuan as of September 30, 2024[15] - The company's inventory increased from 46,800,372.11 yuan at the end of 2023 to 56,516,908.76 yuan as of September 30, 2024[15] - The company's prepayments increased from 2,165,488.47 yuan at the end of 2023 to 7,153,444.98 yuan as of September 30, 2024[15] - The company's other receivables increased slightly from 1,178,489.60 yuan at the end of 2023 to 1,258,629.78 yuan as of September 30, 2024[15] - The company's fixed assets increased from 90,992,259.67 yuan at the end of 2023 to 109,448,452.08 yuan as of September 30, 2024[15] - The company's construction in progress decreased from 67,917,872.68 yuan at the end of 2023 to 59,814,909.47 yuan as of September 30, 2024[15] - The company's total current assets increased from 2,146,138,980.01 yuan at the end of 2023 to 2,213,976,056.13 yuan as of September 30, 2024[15] Sales and Interest Income - Sales expenses rose to 41,923,488.07 yuan, compared to 37,424,561.20 yuan in the same period last year[19] - Interest income for the first three quarters of 2024 was 41,053,469.49 yuan, up from 19,662,304.43 yuan in the same period last year[19]

证券代码：688581 证券简称：安杰思 公告编号：2024-048 （一）审议通过了《关于 2024 年第三季度报告的议案》 监事会认为： 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安杰思医学科技股份有限公司（以下简称"公司"）第二届监事会第十二次 会议于 2024 年 10 月 24 日以现场结合通讯的方式在公司二楼大会议室召开。本次会议 通知已于 2024 年 10 月 14 日以专人送达方式向全体监事发出，本次会议由监事会主席 时百明主持，会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集和召开程序 符合《公司法》和《公司章程》的有关规定。 会议审议通过以下议案并形成决议： 杭州安杰思医学科技股份有限公司 第二届监事会第十二次会议决议公告 公司《2024年第三季度报告》按照《公司法》《公司章程》等相关规定编制，所 包含的信息能从各方面真实地反映公司2024年第三季度的经营情况和财务状况等事项。 报告编制过程中，未发现参与公司《2024年第三季度报告》编制和审议的人员有违反 保密规定的行为。 表决结果 ...

杭州安杰思医学科技股份有限公司 简式权益变动报告书 信息披露义务人：苏州元生私募基金管理合伙企业（有限合伙）－ 苏州工业园区新建元二期创业投资企业（有限合 伙） 住所/通讯地址：苏州工业园区苏虹东路 183 号 14 栋 423 室 执行事务合伙人：苏州元生私募基金管理合伙企业(有限合伙) 股份变动性质： 股份减持（持股比例降至5%） 签署日期： 2024 年 10 月 9 日 1 上市公司 ： 杭州安杰思医学科技股份有限公司 股票上市地： 上海证券交易所 股票简称 ： 安杰思 股票代码 ： 688581 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》（以下简称 "《证券法》"）、《上市公司收购管理办法》（以下简称"《收购管理办法》"）、 《公开发行证券的公司信息披露内容与格式准则第 15 号--权益变动报告书》 （以下简称"《准则 15 号》"）等相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之冲突。 三、依据《证券法》《收购管理办法》及《准则 15 号》的规定，本报告书 已 ...

证券代码：688581 证券简称：安杰思 公告编号：2024-047 杭州安杰思医学科技股份有限公司 关于持股 5%以上股东减持股份至 5% 的权益变动提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三、本次权益变动前后持有的股份数量及比例 | 股东名称 | 本次权益变动前持有股份 | | 本次权益变动后持有股份 | | | --- | --- | --- | --- | --- | | | 股数（股） | 占总股本比例 | 股数（股） | 占总股本比例（%） | | | | （%） | | | | 新建元 | 4,050,635 | 5.0095 | 4,042,940 | 5.0000 | 四、其他情况说明 1、本次权益变动为新建元履行减持股份计划，不触及要约收购，不涉及资 金来源，具体内容详见公司 2024 年 8 月 16 日在上海证券交易所网站披露的《杭 州安杰思医学科技股份有限公司股东减持股份计划公告》（公告编号：2024-041）。 重要内容提示： 公司于近日收到新建元出具的《简式权益变动报告书》， ...

证券代码：688581 证券简称：安杰思 公告编号：2024-046 杭州安杰思医学科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/8，由董事长提议 | | --- | --- | | 回购方案实施期限 | 2024/2/7~2025/2/6 | | 预计回购金额 | 3,000 万元~5,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 40.14 | | 累计已回购股数占总股本比 | 0.50% | | 例 | | | 累计已回购金额 | 万元 3,096.79 | | 实际回购价格区间 | 元/股~82.70 元/股 72.95 | 注：上述累计已回购股份数占总股本比例中的总股本已按照送股后的总股本 80,858,800 股计算。 一、 回购股份的基本情况 202 ...

Group 1: Company Overview - Company Name: Anjisi Medical Technology Co., Ltd. [2] - Stock Code: 688581 [1] Group 2: R&D Investments and Innovations - The company emphasizes product R&D innovation and has increased investment in this area [2] - Current product developments include endoscopic therapy, fiber imaging technology, and robotic assistance [2] - New products such as interchangeable hemostatic clips are entering the registration phase, with fifth and sixth generation clips under development [2] - In the ERCP field, the company has launched innovative coated guidewires, improving insertion success rates [2] Group 3: International Market Expansion - Overseas sales revenue increased by 35.28% compared to the same period last year [3] - Growth rates by region: Asia-Pacific 82.86%, North America 68.49%, South America 53.74% [3] - Self-owned brand sales account for nearly 30% of total sales [3] - The company plans to expand product lines, sales channels, and academic promotions to enhance market coverage and pricing power [3] Group 4: Production Capacity and Delays - The "annual production of 10 million medical endoscope devices and instruments" project has completed construction and relocated production facilities [3] - The delay in production is due to adjustments in the office area and exhibition hall renovations, which will not impact overall production [3]

证券代码：688581 证券简称：安杰思 公告编号：2024-045 杭州安杰思医学科技股份有限公司 关于参加2024年半年度科创板医疗器械及医疗设备 专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2024 年 09 月 19 日(星期四) 下午 14:00-16:00 投资者可于 2024 年 09 月 10 日(星期二) 至 09 月 18 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@bioags.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 董事长：张承 杭州安杰思医学科技股份有限公司（以下简称"公司"）已于 2024 年 08 月 09 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年度的经营成果、财务状况，公司参加了由上交所于 2024 年 09 月 19 日下午 14:00-16:00 主办的 2024 年半年度科创板医疗器械及医疗设备专 ...